AsianScientist (Mar. 4, 2019) – STA Pharmaceutical (WuXi STA), a subsidiary of WuXi AppTec, and Swiss biotech company BioLingus have announced the formation of an exclusive technology and marketing collaboration for sublingual delivery—the administration of drugs via tissues under the tongue.
For drugs to be delivered under the tongue, they need to be stabilized and encapsulated. BioLingus has developed a novel, patented platform to package small molecules, peptides and proteins for sublingual delivery. Such drugs are currently administered to patients via injection.
Under the terms of the collaboration, WuXi STA will have exclusive access to BioLingus technology for sublingual and buccal delivery in the contract development and manufacturing organization (CDMO) sector. The collaboration will help further integrate the advantages of WuXi STA drug product services and expedite the development of BioLingus’ pipeline and usage of sublingual delivery technology.
“We entered into this exclusive collaboration with WuXi STA for this technology in the CDMO sector for a number of reasons. Principally, WuXi STA is one of the world leaders in this field, with an integrated chemistry, manufacturing and controls platform from pre-clinical development to commercialization. Furthermore, this partnership will help us develop our own client base on a global scale faster and more broadly than we could do on our own.” said Mr. Yves Decadt, CEO of BioLingus.
Dr. Minzhang Chen, CEO of WuXi STA, added that the collaboration will offer more economical, convenient and effective delivery solutions for patients globally.
Source: WuXi AppTec; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.